EnGene Therapeutics raised to overweight from neutral by Piper Sandler
ENGN•Piper Sandler raised its rating on EnGene Therapeutics to overweight from neutral.
Related News
Embraer signs long-term maintenance services deal with Mexicana
ERJ•
Upland Software to attend 7th annual Needham Virtual Tech Week
UPLD•
Nexxen Q3 net income more than doubles to $10.43 million
NEXN•
Twist Bioscience Q4 revenue beats analyst expectations
TWST•
Chicago Atlantic BDC Q3 net investment income falls 13% year over year to $8.3 million
LIEN•